Aurora Cannabis Inc. (NYSE:ACB) Expected to Announce Quarterly Sales of $40.58 Million

Analysts predict that Aurora Cannabis Inc. (NYSE:ACBGet Rating) will announce $40.58 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Aurora Cannabis’ earnings. The highest sales estimate is $42.80 million and the lowest is $37.95 million. Aurora Cannabis posted sales of $43.56 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 6.8%. The business is scheduled to announce its next quarterly earnings report after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Aurora Cannabis will report full year sales of $179.38 million for the current financial year, with estimates ranging from $172.35 million to $186.16 million. For the next fiscal year, analysts anticipate that the company will report sales of $194.80 million, with estimates ranging from $177.88 million to $221.68 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Aurora Cannabis.

Aurora Cannabis (NYSE:ACBGet Rating) last announced its earnings results on Thursday, February 10th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.25). The company had revenue of $48.07 million during the quarter, compared to analyst estimates of $45.87 million. Aurora Cannabis had a negative return on equity of 11.52% and a negative net margin of 167.83%.

A number of brokerages recently weighed in on ACB. Cantor Fitzgerald reduced their target price on shares of Aurora Cannabis from C$10.75 to C$7.60 in a research note on Friday, February 11th. Zacks Investment Research raised shares of Aurora Cannabis from a “sell” rating to a “hold” rating in a research report on Monday, January 31st. Finally, CIBC cut their price target on shares of Aurora Cannabis from C$9.25 to C$6.50 in a research report on Thursday, February 3rd. Three equities research analysts have rated the stock with a sell rating and seven have issued a hold rating to the stock. According to MarketBeat.com, Aurora Cannabis currently has a consensus rating of “Hold” and an average target price of $6.98.

Shares of NYSE ACB opened at $2.93 on Friday. The company has a quick ratio of 3.70, a current ratio of 4.92 and a debt-to-equity ratio of 0.19. Aurora Cannabis has a 1-year low of $2.79 and a 1-year high of $10.64. The company has a fifty day moving average price of $3.48 and a 200 day moving average price of $4.98.

Hedge funds have recently modified their holdings of the company. ETF Managers Group LLC raised its holdings in Aurora Cannabis by 1.5% in the 4th quarter. ETF Managers Group LLC now owns 11,435,872 shares of the company’s stock valued at $62,897,000 after acquiring an additional 169,935 shares during the period. Bank of Montreal Can raised its stake in shares of Aurora Cannabis by 6.4% during the fourth quarter. Bank of Montreal Can now owns 934,668 shares of the company’s stock valued at $5,206,000 after acquiring an additional 56,423 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Aurora Cannabis by 78.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 667,099 shares of the company’s stock valued at $3,609,000 after acquiring an additional 292,222 shares during the last quarter. TD Asset Management Inc. raised its stake in Aurora Cannabis by 7.8% during the third quarter. TD Asset Management Inc. now owns 659,000 shares of the company’s stock worth $4,562,000 after buying an additional 47,662 shares during the last quarter. Finally, Ausdal Financial Partners Inc. bought a new position in Aurora Cannabis during the fourth quarter worth $3,465,000. 15.47% of the stock is currently owned by institutional investors.

Aurora Cannabis Company Profile (Get Rating)

Aurora Cannabis Inc produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients.

Featured Articles

Get a free copy of the Zacks research report on Aurora Cannabis (ACB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aurora Cannabis (NYSE:ACB)

Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.